Difference between revisions of "PEComa"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT[0-9]{8})" to " [$1 Clinical Trials Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 39: | Line 39: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''AMPECT:''' Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. [https://doi.org/10.1200/jco.21.01728 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601264/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34637337/ PubMed] [https://clinicaltrials.gov/ | + | # '''AMPECT:''' Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. [https://doi.org/10.1200/jco.21.01728 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601264/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34637337/ PubMed] [https://clinicaltrials.gov/study/NCT02494570 Clinical Trials Registry] |
[[Category:PEComa regimens]] | [[Category:PEComa regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] | ||
Revision as of 12:35, 25 June 2023
Section editor transclusions Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
nab-Sirolimus monotherapy
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence | |
|---|---|---|---|
Wagner et al. 2021 (AMPECT)
|
2016-2018 | Phase 2 (RT) |
Targeted therapy
- Sirolimus protein-bound particles (Fyarro) 100 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article contains dosing details in manuscript link to PMC article PubMed Clinical Trials Registry